Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a mindfulness app rewire Teens' brains to stop overthinking?

NCT ID NCT04697966

Knowledge-focused Sponsor: Mclean Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how a mindfulness app might help teenagers (ages 13-18) who tend to ruminate—getting stuck in repetitive negative thoughts. Participants will be randomly assigned to use the app or a control activity, and will have brain scans and cognitive tests before and after. The goal is to understand how the app changes brain function and attention, and to predict which teens benefit most.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 158 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2021

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

13 to 18 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Both genders, all ethnicities (see Section: Inclusion of Women and Minorities) * Ages 13-18 years * Written informed assent/consent from adolescent and parent/guardian * English as a first language or English fluency * Right-handed * Personal iPhone or Android smartphone * CRSQ rumination subscale score * If on psychotropic medication, must be on stable dose for at least 2 months Exclusion Criteria: * History or current diagnosis of any of the following DSM-5 disorders: schizophrenia spectrum or other psychotic disorder, bipolar disorder, substance/alcohol use disorder within the past 12 months or lifetime severe substance/alcohol use disorder. * Systemic medical or neurological illness that could impact fMRI measures of cerebral blood flow * Failure to meet standard exclusion criteria for fMRI scanning (e.g. pregnancy, claustrophobia, cardiac or neural pacemakers, surgically implanted metal devices, cochlear implants, metal objects in the body) * History of seizure disorder, or head trauma with loss of consciousness \> 2 mins * Serious or unstable medical illness (e.g., cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease) * Participants with active suicidal ideation will be immediately referred to appropriate clinical treatment. * Current or past treatment with mindfulness-based psychotherapy (e.g., MBCT, DBT or ACT) * Exposure to in-person or app-based mindfulness/meditation course (at least 300 mins of past practice)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rumination are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rumination disorder Rumination Syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rumination

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • McLean Hospital

    RECRUITING

    Belmont, Massachusetts, 02478, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.